Perspectives and practices of ototoxicity monitoring

Simple item page
dc.citation.issue1
dc.citation.volume67
dc.contributor.authorPaken J
dc.contributor.authorGovender CD
dc.contributor.authorPillay M
dc.contributor.authorSewram V
dc.coverage.spatialSouth Africa
dc.date.accessioned2023-09-07T21:53:08Z
dc.date.accessioned2023-09-21T22:15:09Z
dc.date.available2020-05-19
dc.date.available2023-09-07T21:53:08Z
dc.date.available2023-09-21T22:15:09Z
dc.date.issued2020-05-19
dc.date.updated2023-09-07T21:24:26Z
dc.description© 2020. The Authors. Licensee: AOSIS.en_US
dc.description.abstractBackground: Treatment of cancer with cisplatin can result in hearing loss. Given the increasing burden of cancer in Africa, appropriate and timely identification, intervention and management of hearing loss in affected patients is of paramount importance. Objectives: This study describes the perspectives and practices of healthcare professionals in relation to cisplatin-associated ototoxicity at an institution treating patients diagnosed with cancer. Method: A concurrent triangulation study design was used to collect quantitative data from seven oncologists, nine nurses and 13 pharmacists using self-administered questionnaires, and qualitative data from four audiologists through semi-structured interviews for this hospital-based study, conducted in South Africa. Results: Levels of awareness of cisplatin-associated ototoxicity varied with only 33% of the nursing personnel being aware in comparison to the oncologists and pharmacists. Oncologists were identified as the main custodians for providing information to patients. Whilst 82% of the participants considered the audiologist to be part of the oncology team, there was no provision for ototoxicity monitoring in the chemotherapy protocols, nor any ototoxicity-monitoring programme in place. There was no evidence that knowledge of cisplatin-associated ototoxicity translated into an appropriate management strategy for such patients. Conclusion: Healthcare personnel overseeing the care and management of cancer patients need to improve their awareness of ototoxicity and refer timeously for audiological evaluation. Audiologists require greater awareness of monitoring programmes to appropriately implement and manage such programmes within a cancer platform and be part of a multidisciplinary team.
dc.format.extente1-e10
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/32501032
dc.identifier.citationPaken J, Govender CD, Pillay M, Sewram V. (2020). Perspectives and practices of ototoxicity monitoring.. S Afr J Commun Disord. 67. 1. (pp. e1-e10).
dc.identifier.doi10.4102/sajcd.v67i1.685
dc.identifier.eissn2225-4765
dc.identifier.elements-typejournal-article
dc.identifier.harvestedMassey_Dark
dc.identifier.issn0379-8046
dc.identifier.urihttp://hdl.handle.net/10179/20126
dc.languageeng
dc.publisherAOSIS
dc.relation.isPartOfS Afr J Commun Disord
dc.rightsCC BY 4.0en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.subjectSouth Africa
dc.subjectawareness
dc.subjectcervical cancer
dc.subjectcisplatin
dc.subjecthealthcare personnel.
dc.subjectototoxicity
dc.subjectAntineoplastic Agents
dc.subjectCisplatin
dc.subjectFemale
dc.subjectHealth Knowledge, Attitudes, Practice
dc.subjectHearing Loss
dc.subjectHumans
dc.subjectMale
dc.subjectMedical Oncology
dc.subjectNeoplasms
dc.subjectOtotoxicity
dc.subjectQualitative Research
dc.subjectSouth Africa
dc.subjectSurveys and Questionnaires
dc.titlePerspectives and practices of ototoxicity monitoring
dc.typeJournal article
pubs.elements-id445259
pubs.organisational-groupOther
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
445259.pdf
Size:
660.48 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles